Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing.

The combination treatment of BTZ with toyocamycin, either at 0.5 mg/kg or 1.0 mg/kg, showed a trend toward enhancing anti-tumor activity represented as smaller tumor volumes when compared with BTZ or toyocamycin alone ( Figures 6a and b ).

also in 53,322 other papers